Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eikon Therapeutics, Inc.EIKN · Entity 5380 | Director | March 02, 2026 | March 04, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | Director · Executive Chair | November 07, 2022 | November 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eikon Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.88 · Expires 2036-03-01 | Direct | 25,873 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 25,873 · Balance 25,873 F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.
Merck & Co., Inc.
Report date November 07, 2022 · Filed November 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 936,422.063 |
Reported balance
After 2022-11-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-11-07 · Exercise / conversion · Acquired 235,769 · Balance 936,422.063 |
| Common StockSEC Table I · non-derivative | Direct | 911,508.063 |
Reported balance
After 2022-11-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-11-07 · Sale · Disposed 24,914 · Balance 911,508.063 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.7400 to $98.7400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 785,374.063 |
Reported balance
After 2022-11-07 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2022-11-07 · Sale · Disposed 126,134 · Balance 785,374.063 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.7500 to $99.7500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 700,653.063 |
Reported balance
After 2022-11-07 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2022-11-07 · Sale · Disposed 84,721 · Balance 700,653.063 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.7600 to $100.3400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F4: Holdings include shares acquired in dividend reinvestment transactions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.06 · Expires 2026-05-09 | Direct | 0 |
Reported balance
After 2022-11-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-07 · Exercise / conversion · Disposed 235,769 · Balance 0 F6: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. |
| Common Stock - 401(k) PlanSEC Table I · non-derivative | IndirectBy 401(k) | 4,481.1286 |
Reported balance
Holding disclosure · report date 2022-11-07 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 4,481.1286 F5: Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.7400 to $98.7400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.7500 to $99.7500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.7600 to $100.3400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F4: Holdings include shares acquired in dividend reinvestment transactions.
F5: Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan.
F6: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EXXON MOBIL CORP
Report date May 25, 2022 · Filed May 26, 2022
Section 16 reporting ended · disclosed 2022-05-26. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 22:01 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | GrantStock Option (Right to Buy) · Derivative | 25,873 | $0.00 Strike: $14.88 | $0.00 |
DisclosureSEC source: 0001193125-26-091783 · ownership.xml · derivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,873 Underlying: Common Stock · 25,873 shares Expires 2036-03-01 F1 · derivative.exercise_date: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 23:33 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | PurchaseCommon Stock | 111,111 | $18.00 | $1,999,998.00 |
DisclosureSEC source: 0001193125-26-041555 · ownership.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,111 Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 235,769 | $0.00 Strike: $53.06 | $0.00 |
DisclosureSEC source: 0001127602-22-025118 · form4.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 235,769 shares Expires 2026-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 84,721 | $100.07 | $8,477,717.00 |
DisclosureSEC source: 0001127602-22-025118 · form4.xml · nonDerivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,653.063 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.7600 to $100.3400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F4 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 126,134 | $99.42 | $12,540,835.11 |
DisclosureSEC source: 0001127602-22-025118 · form4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 785,374.063 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.7500 to $99.7500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 24,914 | $98.45 | $2,452,880.46 |
DisclosureSEC source: 0001127602-22-025118 · form4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 911,508.063 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.7400 to $98.7400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 235,769 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025118 · form4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 936,422.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2022 Filed Nov 7, 2022 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 235,000 | $0.00 Strike: $53.06 | $0.00 |
DisclosureSEC source: 0001127602-22-025018 · form4.xml · derivative · entry 9 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,769 Underlying: Common Stock · 235,000 shares Expires 2026-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| November 04, 2022 Filed Nov 7, 2022 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 34,810 | $99.08 | $3,448,988.72 |
DisclosureSEC source: 0001127602-22-025018 · form4.xml · nonDerivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,653.063 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.9800 to $99.2800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F5 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 04, 2022 Filed Nov 7, 2022 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 200,190 | $98.53 | $19,725,241.19 |
DisclosureSEC source: 0001127602-22-025018 · form4.xml · nonDerivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 735,463.063 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.9700 to $98.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 04, 2022 Filed Nov 7, 2022 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 235,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025018 · form4.xml · nonDerivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 935,653.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 235,000 | $0.00 Strike: $53.06 | $0.00 |
DisclosureSEC source: 0001127602-22-025018 · form4.xml · derivative · entry 8 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,769 Underlying: Common Stock · 235,000 shares Expires 2026-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 20,383 | $99.09 | $2,019,804.47 |
DisclosureSEC source: 0001127602-22-025018 · form4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,653.063 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.0600 to $99.2000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 214,617 | $98.68 | $21,178,083.63 |
DisclosureSEC source: 0001127602-22-025018 · form4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 721,036.063 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.0500 to $99.0500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 235,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025018 · form4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 935,653.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 134,172 | $0.00 Strike: $53.06 | $0.00 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · derivative · entry 15 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 705,769 Underlying: Common Stock · 134,172 shares Expires 2026-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F10 · derivative.exercise_date: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. F9 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 165,828 | $0.00 Strike: $58.08 | $0.00 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · derivative · entry 14 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 165,828 shares Expires 2025-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 94,339 | $100.40 | $9,471,739.37 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 11 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,653.063 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.0100 to $101.0100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F6 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 205,661 | $99.68 | $20,500,103.39 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 10 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 794,992.063 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.0000 to $100.0000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 134,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 9 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,653.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 20:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 165,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 8 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866,481.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $58.08 | $0.00 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · derivative · entry 13 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,828 Underlying: Common Stock · 300,000 shares Expires 2025-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | GiftCommon Stock | 1,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 7 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,653.063 Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | GiftCommon Stock | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 702,123.063 Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | GiftCommon Stock | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 704,573.063 Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 700 | $101.05 | $70,732.97 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 706,283.063 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.0300 to $101.0700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 96,981 | $100.22 | $9,719,843.14 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 706,983.063 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.9800 to $100.9800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 202,319 | $99.61 | $20,152,287.47 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 803,964.063 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.9700 to $99.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024871 · form4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,006,283.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2022 Filed Nov 1, 2022 20:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $58.08 | $0.00 |
DisclosureSEC source: 0001127602-22-024610 · form4.xml · derivative · entry 10 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,828 Underlying: Common Stock · 300,000 shares Expires 2025-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F10 · derivative.exercise_date: The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. F8 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| October 31, 2022 Filed Nov 1, 2022 20:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 229,302 | $101.03 | $23,167,321.20 |
DisclosureSEC source: 0001127602-22-024610 · form4.xml · nonDerivative · entry 7 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 706,283.063 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.3600 to $101.3100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F6 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 31, 2022 Filed Nov 1, 2022 20:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 70,698 | $99.82 | $7,056,770.36 |
DisclosureSEC source: 0001127602-22-024610 · form4.xml · nonDerivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 935,585.063 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.3300 to $100.3200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| October 31, 2022 Filed Nov 1, 2022 20:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024610 · form4.xml · nonDerivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,006,283.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 567,084 | $0.00 Strike: $56.49 | $0.00 |
DisclosureSEC source: 0001127602-22-024610 · form4.xml · derivative · entry 9 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 567,084 shares Expires 2024-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F9 · derivative.exercise_date: The option became exercisable in equal installments on 5/9/2015, 5/9/2016 and 5/9/2017. F8 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 178,363 | $100.80 | $17,978,687.18 |
DisclosureSEC source: 0001127602-22-024610 · form4.xml · nonDerivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 706,283.063 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.6500 to $100.9725, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 313,232 | $100.25 | $31,402,729.60 |
DisclosureSEC source: 0001127602-22-024610 · form4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884,646.063 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.6400 to $100.6400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 75,489 | $99.15 | $7,484,855.13 |
DisclosureSEC source: 0001127602-22-024610 · form4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,197,878.063 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.6100 to $99.6000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., anysecurity holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 20:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 567,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024610 · form4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,273,367.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2022 Filed Aug 19, 2022 19:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 28,532 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-021362 · form4.xml · derivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,532 Underlying: Common Stock · 28,532 shares Expires 2023-08-03 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest in full and are distributed as shares of Merck & Co., Inc. common stock on 8/3/2023. Read SEC document |
| May 03, 2022 Filed May 5, 2022 20:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 28,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013508 · form4.xml · derivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,703 Underlying: Common Stock · 28,703 shares Expires 2023-05-03 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest in full and are distributed as shares of Merck & Co., Inc. common stock on 5/3/2023. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 21:15 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 119,488 | $73.51 | $8,783,562.88 |
DisclosureSEC source: 0001127602-22-007005 · form4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 706,283.063 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 22:47 UTC | EXXON MOBIL CORP XOM · Entity 32533 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-000634 · form4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,500 F1 · price: Restricted stock grant. Read SEC document |
| November 09, 2021 Filed Nov 10, 2021 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (Right to Buy) · Derivative | 663,881 | $0.00 Strike: $43.65 | $0.00 |
DisclosureSEC source: 0001127602-21-028802 · form4.xml · derivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 663,881 shares Expires 2023-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F5 · shares: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016. F5 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| November 09, 2021 Filed Nov 10, 2021 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 29,615 | $83.23 | $2,464,865.33 |
DisclosureSEC source: 0001127602-21-028802 · form4.xml · nonDerivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 586,795.063 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.9500 to $83.5800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 09, 2021 Filed Nov 10, 2021 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 634,266 | $82.22 | $52,146,496.32 |
DisclosureSEC source: 0001127602-21-028802 · form4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 616,410.063 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.9300 to $82.9200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 09, 2021 Filed Nov 10, 2021 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 663,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-028802 · form4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250,676.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:34 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 329,082 | $0.00 Strike: $75.99 | $0.00 |
DisclosureSEC source: 0001127602-21-015734 · form4.xml · derivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,082 Underlying: Common Stock · 329,082 shares Expires 2031-05-03 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 16:14 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 175,249 | $72.62 | $12,726,582.38 |
DisclosureSEC source: 0001127602-21-008561 · form4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 586,795.063 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/18. Performance shares were paid out at 166 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2020. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 17:25 UTC | EXXON MOBIL CORP XOM · Entity 32533 | GrantCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-000922 · form4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 F1 · price: Restricted stock grant. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 21:45 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 144,866 | $81.74 | $11,840,941.22 |
DisclosureSEC source: 0001127602-20-028825 · form4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,546.063 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.40 to $82.33, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.